Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Buscar Study Connect
Ícono de BMS, estudio Activo, no reclutando

Active, Not Recruiting

ID del estudio CA209-653  |   NCT02940639

Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced Renal Cell Carcinoma After Prior Therapy

Ícono de advertencia
Lo sentimos, este estudio ya no acepta nuevos participantes, pero aún está en curso.
Puede hacer clic en el botón “Verificar su Elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Comuníquese con nosotros si necesita ayuda
855-907-3286

Resumen

  • Ícono de género masculino y femenino
  • 18+
  • Ícono de BMS, estudio Activo, no reclutando
    Active, Not Recruiting

Descripción general

A Real-Life Study to Evaluate Efficacy and Safety of Nivolumab in Patients with Advanced Renal Cell Carcinoma after prior therapy.

Criterios clave de elegibilidad

Inclusion Criteria: - ≥ 18 years - diagnosis of advanced RCC (confirmed by histology or cytology) - treatment decision to initiate a treatment with nivolumab for the first time for the treatment of RCC (according to the label approved in Germany) has already been taken - signed informed consent Exclusion Criteria: - diagnosis of a cancer other than advanced RCC within the past 5 years, ie, a cancer other than RCC that requires systemic or other treatment. Patients that have been treated curatively more than 5 years ago with no evidence of recurrence and prostate cancer patients in active surveillance can be included - previous treatment with nivolumab and/or ipilimumab - current active participation in an interventional clinical trial for treatment of their advanced RCC.

Opciones de tratamiento

Brazos del estudio

INTERVENCIÓN ASIGNADA

Brazos del estudio

Advanced RCC patients initiating Nivo for the first time

INTERVENCIÓN ASIGNADA

Brazos del estudio

Nivolumab and ipilimumab combination therapy (cohort 2)

INTERVENCIÓN ASIGNADA

Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 - Llame 855-907-3286 o Envíenos un correo electrónico

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 -
Llame 855-907-3286 o Envíenos un correo electrónico